Newsroom

Videoconference • Half-Year Results

December 10, 2024

[Replay] Videoconference – H1 2024-25 Results

December 10, 2024

December 10, 2024

Consolidated Half-Year Financial Results

December 10, 2024

December 10, 2024

Medincell and AIC Unveil New Positive Phase 3 Results for mdc-CWM

December 9, 2024

December 9, 2024

Videoconference and publication of half-year financial results, Tuesday, December 10, 2024

November 29, 2024

November 29, 2024

25% Raise in 2024 UZEDY® Revenue Outlook & Key Milestone Reached for Olanzapine LAI clinical Phase 3

November 6, 2024

November 6, 2024

New Phase 3 Positive Results for Olanzapine LAI and Real-World Data on UZEDY®

November 4, 2024

November 4, 2024

Participation in Leading Investor Conferences

October 28, 2024

October 28, 2024

Videoconference • Collaboration with AbbVie (French)

October 10, 2024

Revisiting the nature and pharmacodynamics of tacrolimus metabolites

September 27, 2024

September 27, 2024

New Efficacy, Safety, and Tolerability Data from Pivotal Phase 3 of Olanzapine LAI

September 23, 2024

September 23, 2024

New Treatment Insights into Switching to UZEDY® from Perseris®

September 23, 2024

September 23, 2024